REVIEW ARTICLE
Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery
Abhinav P. Mishra*, Suresh Chandra, Ruchi Tiwari, Ashish Srivastava, Gaurav Tiwari
Article Information
Identifiers and Pagination:
Year: 2018Volume: 12
First Page: 111
Last Page: 123
Publisher ID: TOMCJ-12-111
DOI: 10.2174/1874104501812010111
Article History:
Received Date: 15/7/2018Revision Received Date: 18/9/2018
Acceptance Date: 20/9/2018
Electronic publication date: 23/10/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4. 0 International Public License (CC-BY 4. 0), a copy of which is available at: https://creativecommons. org/licenses/by/4. 0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
In designing of Prodrugs, targeting can be achieved in two ways: site-specified drug delivery and site-specific drug bioactivation. Prodrugs can be designed to target specific enzymes or carriers by considering enzyme-substrate specificity or carrier-substrate specificity in order to overcome various undesirable drug properties. There are certain techniques which are used for tumor targeting such as Antibody Directed Enzyme Prodrug Therapy [ADEPT] Gene-Directed Enzyme Prodrug Therapy [GDEPT], Virus Directed Enzyme Prodrug Therapy [VDEPT] and Gene Prodrug Activation Therapy [GPAT]. Our review focuses on the Prodrugs used in site-specific drug delivery system specially on tumor targeting.